Zykadia

Selected form

Ceritinib

Treatment option: Lymphoma, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Cancer,Lung

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zykadia

Zykadia is the trade name for the synthetic compound Ceritinib, a potent prescription-only medication specifically designed as a targeted anti-cancer drug. It is classified within a modern therapeutic group that focuses on molecular pathways to interrupt the growth signals of certain abnormal cells.

Property	Description
Active ingredient	Ceritinib (INN)
Form	Hard gelatin capsules (Oral)
Pharmacological class	Anaplastic Lymphoma Kinase (ALK) Inhibitor
General Purpose	Systemic control of molecularly-driven disease progression
Origin	Synthetic compound
Manufacturer	Novartis Pharmaceuticals

Zykadia (Ceritinib): Definition and Pharmacological Class

Ceritinib is formally classified as a Kinase Inhibitor, which places it within the larger category of Tyrosine Kinase Inhibitors (TKIs). These agents function by selectively blocking the activity of specific enzymes called kinases, which are often hyperactive in certain disease states. The main purpose of blocking these enzymes is to help stop the proliferation and spread of cells that rely on this abnormal signaling pathway for their growth.

Its mechanism is highly focused on the Anaplastic Lymphoma Kinase (ALK) protein. Ceritinib is a protein kinase inhibitor that primarily acts by inhibiting the ALK-mediated signaling pathway. This means the drug helps provide molecular control over conditions where the ALK protein has become faulty and is driving cell growth, a key feature that differentiates it from less-selective systemic agents.

Composition, Form, and General Therapeutic Purpose

Zykadia is a single-active ingredient product where Ceritinib serves as the sole therapeutic agent. It is provided for oral administration as hard gelatin capsules, making it a form of oral oncology treatment designed for systemic absorption. The capsules contain the active ingredient alongside standard pharmaceutical excipients to ensure stability and proper delivery.

The overarching general purpose of this targeted medicine is to selectively interfere with the abnormal ALK protein and the ALK fusion proteins it creates, thereby limiting the advancement of the disease process. This focused action is the core principle of its therapeutic utility, aiming to control the disease process by striking directly at the identified molecular driver.

What side effects are possible with Zykadia?

Official Safety Profile and Adverse Reactions

The safety profile for Zykadia (Ceritinib) is structured by regulatory bodies (such as the FDA and EMA) to classify potential adverse reactions based on their frequency and the body system affected. These classifications detail which effects are most common versus those that are rare but clinically serious.

Adverse reactions are frequently observed across the Gastrointestinal System (e.g., Diarrhea, Nausea, Vomiting) and Metabolism and Nutrition Disorders (e.g., Hyperglycemia, decreased appetite). These effects are categorized as Very Common (ge 10%) in official documents, alongside fatigue and elevations in liver enzymes ( ALT/ AST).

Serious Adverse Reactions

Specific serious adverse reactions are highlighted in regulatory labeling due to their potential severity. These include Hepatotoxicity (severe liver injury), Interstitial Lung Disease (ILD)/Pneumonitis, and Cardiac Disorders such as QT Interval Prolongation and Bradycardia (slowing of the heart rate).

Population and Monitoring Notes

The official labeling outlines constraints for certain populations. The medicine is not recommended for use in patients with moderate to severe hepatic impairment. Furthermore, the safety and effectiveness of Ceritinib have not been established in the pediatric population.

Regulatory documents mandate specific safety monitoring, requiring the checking of liver function tests (including ALT, AST, and total bilirubin) every two weeks for the first month of treatment, and monthly thereafter. This time-related pattern ensures observation for potential toxicity, consistent with the official label's requirements.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information (e.g., FDA Prescribing Information, EMA SmPC) does not define a standard treatment protocol for an acute, single-event overdose of Zykadia (ceritinib) in humans. The official drug labeling focuses on managing severe adverse reactions, which are considered to be manifestations of drug over-exposure or toxicity that require immediate clinical action.

Immediate medical help is required for any suspected over-exposure or the appearance of severe, life-threatening symptoms associated with this medicine.

Key Signs of Over-exposure Requiring Action (as per Regulatory Documents)

System Affected	High-Risk Presentation (When to Seek Urgent Help)
Cardiovascular	Life-threatening bradycardia (very slow heart rate) or significant QTc interval prolongation (an electrical heart rhythm abnormality).
Hepatic	High-grade liver enzyme elevations (ALT/AST) especially when accompanied by elevated total bilirubin (signs of severe hepatotoxicity).
Gastrointestinal	Severe or intolerable nausea, vomiting, or diarrhea that is unmanageable.
Metabolic	High-grade lipase and amylase elevations (suggesting potential pancreatitis) or severe hyperglycemia (high blood sugar).

Procedural Instructions for Over-exposure

Official regulatory guidelines for managing over-exposure mandate specific actions from a healthcare professional, including withholding the dose, reducing the dose upon recovery, or permanently discontinuing the medication for the most severe or intolerable events, such as life-threatening bradycardia or life-threatening pneumonitis.

Therapeutic Uses of Zykadia

What Zykadia Treats: Main Uses and Benefits

Zykadia (ceritinib) is a medicine applied across therapeutic domains where additional symptomatic support is needed. It is commonly used across conditions presenting with acute episodes and symptoms related to heightened physiological activity.

Zykadia is authorized as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). It is considered relevant when the tumor is confirmed to be anaplastic lymphoma kinase (ALK)-positive.

It is commonly used when short-term symptomatic assistance is needed. This supportive role generally contributes to improved comfort during periods of heightened symptoms, which supports the patient during difficult episodes by easing distress. It is applied in addressing conditions characterized by periods of heightened symptoms, commonly used across conditions presenting with acute episodes.

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Zykadia (ceritinib) is approved for use in adult patients whose tumors are confirmed to be Anaplastic Lymphoma Kinase (ALK)-positive. This genetic biomarker status must be verified by an approved test before starting treatment.

Contraindications and Non-Eligibility

Use of Zykadia is contraindicated in patients with a known hypersensitivity to the drug or any of its components, and in those with congenital long QT syndrome or a persistent Fridericia-corrected QTc interval of ge 500 milliseconds.

Population/Condition	Eligibility Status (Regulatory Basis)
Pediatric Population (<18 years)	Use Not Established (Safety and efficacy not determined)
Pregnancy	Avoid (Potential for fetal harm)
Breastfeeding	Not Recommended (Risk of excretion into milk)
Severe Hepatic Impairment	Conditional Use (Dose must be reduced)
Severe Renal Impairment	Caution (Lack of experience in this population)

Treatment must be permanently discontinued if specific severe toxicities occur, including treatment-related Interstitial Lung Disease (ILD)/pneumonitis, certain concurrent severe elevations in liver enzymes and bilirubin, or QTc prolongation combined with a serious arrhythmia.

What should I know about interactions with other medicines?

Taking Zykadia (ceritinib) concurrently with certain other medicines or products can change its concentration in the body or increase the risk of specific side effects.

Potential Drug Interactions

Interacting Product Category	Effect and Recommendation
Strong CYP3A Inhibitors (e.g., ketoconazole, ritonavir)	Avoid concurrent use; these can significantly increase Zykadia levels, raising the risk of side effects. If use is unavoidable, a dose adjustment of Zykadia is necessary.
Strong CYP3A Inducers (e.g., rifampicin, phenytoin, St. John's Wort)	Avoid concurrent use; these can dramatically lower Zykadia levels, potentially reducing its effectiveness.
QTc-Prolonging Medicines (e.g., certain anti-arrhythmics, antipsychotics)	Increased risk of heart rhythm changes (QTc prolongation). Careful monitoring of heart function and electrolytes may be required.
CYP3A or CYP2C9 Substrates (with narrow therapeutic indices, e.g., alfentanil, warfarin)	Avoid concurrent use; Zykadia can increase the levels of these medicines, potentially leading to increased side effects.
Products Causing Bradycardia (slow heart rate)	Increased risk of slow heart rate. Close monitoring of heart rate and blood pressure is required.

Food and Beverage Interactions

Grapefruit and grapefruit juice must be avoided while taking Zykadia. These products can increase the amount of Zykadia in the bloodstream to a harmful level. Zykadia should be taken with food, as directed, to help achieve appropriate drug exposure.

Mechanism of Action

Selective Kinase Inhibition and Signal Shutdown

Ceritinib acts as a competitive inhibitor that targets the Anaplastic Lymphoma Kinase (ALK) protein and its fusion variants. The compound binds directly and tightly to the enzyme's active site, preventing the ALK protein from consuming ATP (adenosine triphosphate) and achieving activation through autophosphorylation. This action is specific to pathways associated with heightened cell proliferation signals. This molecular shutdown is the key step that leads to a decrease in signaling activity.

Pathway Suppression and Induction of Cell Fate Change

This domain focuses on the downstream cellular consequences of the signaling blockade. Inhibiting ALK starves the cell by suppressing critical survival pathways, including the PI3K/AKT/mTOR and RAS/MAPK networks. This targeted suppression limits the transmission of pro-growth commands, which, in turn, forces the affected cells to undergo Cell Cycle Arrest and Apoptosis (programmed cell death). This mechanism provides focused pathway inhibition over cells dependent on this aberrant signaling.

Limitations from Adaptive Molecular Mechanisms

This domain addresses the biological scenarios where the mechanism may be constrained. The mechanism's efficacy can be limited by the cell's adaptive responses, such as the emergence of secondary ALK mutations (e.g., G1202R) which structurally hinder the drug's binding affinity, or the activation of alternative bypass signaling pathways (e.g., through IGF-1R or EGFR). These changes result in conditions that reduce the inhibitory capacity of the mechanism, allowing the proliferation signals to resume via an alternative pathway.

Dosage and Administration Information

How to Use Zykadia (Ceritinib)

Zykadia is a targeted therapy administered for oral use as hard gelatin capsules. Its administration is structured by guidelines concerning dosage, frequency, and specific intake conditions. These parameters define the standardized protocol for the drug's use in clinical practice.

Standard Administration Protocol

The medication is intended for a long-term, continuous protocol, with treatment generally maintained until clinical evidence suggests disease progression or the onset of unacceptable toxicities. The standard regimen involves taking the medicine once daily, at approximately the same time each day. The recommended starting dosage for adult patients is 450 mg. Dose reduction steps are documented for managing specific medical events, allowing for adjustments down to 300 mg and then 150 mg once daily.

Key Administration Condition	Official Labeled Instruction
Relation to Food	Must be taken without food to achieve the appropriate systemic drug exposure.
Capsule Handling	The hard capsules must be swallowed whole with water; they should not be opened, crushed, or chewed.
Population Adjustments	A specific dose reduction is required for patients with severe hepatic impairment.

Maintaining the Dosing Schedule

Consistency in administration is maintained through specific procedural rules. If a daily dose is missed, instructions advise that the dose may be taken only if the next scheduled dose is due in more than 12 hours. If less than 12 hours remain, the missed dose must be skipped entirely. This protocol ensures the consistent systemic level of Ceritinib without the risk of unintended high exposure. The medicine's use is strictly defined by these procedural constraints.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zykadia (Ceritinib)

Evidence for Use in First-Line ALK-Positive Non-Small Cell Lung Cancer

The primary evidence for using Zykadia in patients who have not previously received systemic therapy for advanced ALK-positive non-small cell lung cancer (NSCLC) comes from a large, open-label, Phase III randomized controlled trial. This study was evaluated in adult patients and was studied for how the medicine compared to standard chemotherapy regimens. Researchers focused on time-based outcomes, particularly Progression-Free Survival (PFS), which measures the time interval until disease progression is observed. They also examined Objective Response Rate (ORR), which reflects the percentage of patients with a measurable tumor change during the study period.

Studies monitored measurements of a longer median Progression-Free Survival (PFS) was reported in the group administered Zykadia compared to the group administered chemotherapy. These findings describe patterns observed in the studies but do not determine whether an individual will respond similarly.

Evidence in ALK-Positive NSCLC Previously Treated with Crizotinib

Zykadia was evaluated in clinical research involving adult patients whose ALK-positive NSCLC had progressed following prior treatment with the ALK inhibitor crizotinib. The initial evidence relied on Phase I/II single-arm trials that primarily monitored the Objective Response Rate (ORR). Later research included a Phase III trial that compared Zykadia to chemotherapy.

In these studies, single-arm trials reported measurements of tumor change, with a median Duration of Response (DOR) being reported across the study population. These findings indicate that the research explored short-term disease control in a patient group where prior targeted therapy was associated with disease progression.

What is Still Uncertain About Zykadia Research

The evidence landscape is limited by a few key research gaps. Comparative evidence is lacking for direct, head-to-head trials between Zykadia and other newer targeted inhibitors. The current research base includes studies where Zykadia was compared against standard chemotherapy.

Additionally, the final long-term outcomes, particularly Overall Survival (OS), may not provide a clear picture of long-term study patterns. This is because patient transitions between different ALK-targeted therapies as their disease progresses complicate the ability to definitively isolate long-term patterns associated only with Zykadia. The evidence is not established in the pediatric population, meaning research for this group remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Zykadia (FAQ)

Q: What is Zykadia (Ceritinib) approved to treat?

Official product information indicates Zykadia is approved for use in adult patients who have metastatic non-small cell lung cancer (NSCLC). This specific use is for tumors confirmed to be Anaplastic Lymphoma Kinase (ALK)-positive by an approved test.

Q: How long will I need to take Zykadia?

The medicine is generally used in a continuous, long-term protocol, according to regulatory documents. Treatment is intended to be maintained until clinical testing shows that the disease has progressed or if side effects occur that are deemed unmanageable.

Q: How should I dispose of unused Zykadia?

To ensure safety, Zykadia should not be disposed of in household trash or by flushing it down the toilet. Official instructions state that disposal should follow local pharmaceutical waste regulations or use an authorized drug take-back program.

Q: What monitoring is required while taking Zykadia?

The official product information requires routine monitoring for several potential effects. This includes regular checks of liver function, blood glucose levels, heart rate, and blood pressure. An electrocardiogram (ECG) may also be used to check for changes to heart rhythm.

Q: What happens if I vomit shortly after taking Zykadia?

Product labeling states that if vomiting occurs soon after taking a dose, a replacement dose should not be taken. Patients are instructed to continue with only their next scheduled dose at the usual time.

Q: Can Zykadia be used if I have severe kidney problems (renal impairment)?

Regulatory documents note that for patients with mild to moderate kidney problems, no dose adjustment is required. Official guidance suggests caution when used in patients with severe kidney problems because there is limited experience with the drug in this specific group.

Q: How does Zykadia get eliminated from the body (half-life)?

Pharmacokinetic data from the product label indicates how the body processes the medicine. The time it takes for half of the drug to be eliminated from the bloodstream, known as the terminal half-life, is approximately 40 hours following a single oral dose.

Q: What are the most common side effects from the clinical studies?

Data from clinical studies indicate that the most frequently reported side effects were gastrointestinal issues. The most common adverse reactions, reported in over 80% of patients in clinical studies, include diarrhea and nausea, followed by vomiting, stomach pain, and general fatigue.

Q: What is the molecular formula of Ceritinib?

The active ingredient, Ceritinib, is a synthetic compound. Its specific molecular formula, as documented in official regulatory databases, is C28 H36 ClN5 O3 S. This formula describes the exact atoms that make up the drug molecule.

Q: How do I know if the drug is working (signs of effectiveness)?

Clinical trials primarily measure effectiveness using two key metrics: Objective Response Rate (ORR) and Progression-Free Survival (PFS). ORR refers to the percentage of patients whose tumors shrink significantly, and PFS is the time a patient lives without the disease worsening.

How should Zykadia be stored and disposed of?

How to Store and Dispose of Zykadia?

Zykadia (ceritinib) storage and disposal must adhere to official label conditions to maintain product integrity and ensure safety.

Storage Requirements

The capsules must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The medication should be kept in the original container, which must be tightly closed, and stored away from light, heat, and moisture. To protect children, the medicine must be kept out of their sight and reach.

Disposal Instructions

Unused or expired Zykadia should not be thrown in household trash or flushed down the toilet. Disposal must follow local pharmaceutical waste regulations, often utilizing official drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.